TURNER DANIEL K III 4
4 · Orexigen Therapeutics, Inc. · Filed Dec 23, 2010
Insider Transaction Report
Form 4
TURNER DANIEL K III
Director
Transactions
- Sale
Common Stock
2010-12-23−48,057→ 498,712 total(indirect: By Montreux Equity Partners II, SBIC, LP, Montreux Equity Partners III, SBIC, LP and related funds) - Sale
Common Stock
2010-12-22$8.25/sh−51,943$428,530→ 546,769 total(indirect: By Montreux Equity Partners II, SBIC, LP, Montreux Equity Partners III, SBIC, LP and related funds)
Footnotes (6)
- [F1]25,971 of the 51,943 share sold, were sold by Montreux Equity Partners II SBIC, L.P. 25,972 of the 51,943 shares sold, were sold by Montreux Equity Partners III SBIC, L.P.
- [F2]Of the total 546,769 total shares beneficially owned following the reported transaction, 173,385 shares are held by Montreux Equity Partners II SBIC, L.P. and 373,384 shares are held by Montreux Equity Partners III SBIC, L.P.
- [F3]The reported securities are owned directly by Montreux Equity Partners II SBIC, L.P., ("MEP II") and Montreux Equity Partners III SBIC, L.P, ("MEP III"). The voting and disposition of the shares held by MEP II and MEP III are determined by Montreux Equity Management II SBIC, LLC, ("MEM II") and Montreux Equity Management III SBIC, LLC, ("MEM III"), respectively. Mr. Turner is a managing member of MEM II and MEM III. Mr. Turner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- [F4]24,029 of the 48,057 share sold, were sold by Montreux Equity Partners II SBIC, L.P. 24,028 of the 48,057 shares sold, were sold by Montreux Equity Partners III SBIC, L.P.
- [F5]The sale price of the 48,057 shares reported in this Form 4 was between the range of $8.27 per share and $8.05 per share, with an average sale price of $8.1502. Full information regarding the number of shares sold at each separate price will be provided to the Commission staff upon request.
- [F6]Of the total 498,712 total shares beneficially owned following the reported transaction, 149,356 shares are held by Montreux Equity Partners II SBIC, L.P. and 349,356 shares are held by Montreux Equity Partners III SBIC, L.P.